Vanguard Fiduciary Trust
REVB icon

Vanguard Fiduciary Trust’s Revelation Biosciences REVB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Hold
13,127
– – ﹤0.01% 4023
2026
Q1 		$15.8K Buy
+13,127
New +$25.4K ﹤0.01% 3972

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Fiduciary Trust's REVB Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Revelation Biosciences (REVB) position steady in Q2 2026 at 13,127 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4023.

Vanguard Fiduciary Trust first reported a position in REVB in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.8K in Q1 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • Vanguard Fiduciary Trust held 13,127 shares of Revelation Biosciences worth $13.5K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Revelation Biosciences share count unchanged in Q2 2026.
  • Revelation Biosciences made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4023 holding.
  • Vanguard Fiduciary Trust first reported a position in Revelation Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Revelation Biosciences position peaked at $15.8K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.